33 C
Vientiane
Saturday, May 10, 2025
spot_img
Home Blog Page 651

Voithru Wraps Up 2nd t ōtus Translation Contest with Great Success

Record-Breaking 3,586 Translators Participated in t ōtus Translation Contest

SEOUL, South Korea, Feb. 17, 2025 /PRNewswire/ — On February 8, 2025, VOITHRU, a leader in cultural content translation, successfully concluded its 2nd tōtus Translation Contest Award Ceremony at its headquarters.

*February 8, 2025 – Seoul, South Korea – Winners of the 2nd tōtus Translation Contest pose with VOITHRU CEO Sangheon Lee (center) during the award ceremony.
*February 8, 2025 – Seoul, South Korea – Winners of the 2nd tōtus Translation Contest pose with VOITHRU CEO Sangheon Lee (center) during the award ceremony.

The contest, held in October 2024, was supported by Kakao Piccoma, Code Crayon, Tooneed Entertainment, C&C Revolution, and DCCENT—which provided translation materials—with additional sponsorship from the Korean Society of Translators and the Committee of ITT.

The competition featured six categories: Korean video translation (into English, Japanese, or Traditional Chinese) and Korean webtoon translation (into English, Japanese, or Spanish). Participants submitted their translations in the category of their choice.

The event saw record-breaking participation, with 3,586 translators worldwide. A total of 18 winners were selected: one Grand Prize winner, one 1st runner-up, and one 2nd runner-up from each category. Grand Prize winners received KRW 5 million, 1st runners-up were awarded KRW 2 million, and 2nd runners-up received KRW 1 million.

Jeehyung Lee, the Grand Prize winner in the Korean-English short-form video category, shared her thoughts, saying, “This contest was a fantastic opportunity to showcase my translation skills and grow professionally. I am deeply grateful to VOITHRU and the sponsors for creating such a meaningful contest.”

Sangheon Lee, CEO of VOITHRU, added, “Through this contest, we aimed to highlight the fascination of cultural content translation, particularly for short-form videos and webtoons. Aligning with the growing global interest in Korean cultural content, we hope this initiative fosters talented translators.”

Agoda’s Guide to 7 Asian Street Food Havens

SINGAPORE, Feb. 17, 2025 /PRNewswire/ — Digital travel platform Agoda highlights a list of seven cities in Asia that specialize in street food, where culinary delights await travelers eager to explore diverse flavors. From the bustling markets of Bangkok to the aromatic stalls of Seoul, these destinations offer a feast for the senses as well as a compelling reason to return.

Recent research from Agoda reveals that tasting local cuisines consistently ranks among the top reasons for revisiting destinations. Street food, in particular, offers an authentic taste of local culture, making it a must-do experience for any traveler.

Andrew Smith, Senior Vice President, Supply at Agoda shared, “Street food is the heartbeat of many Asian cities, and Agoda is excited to spotlight these culinary havens. Whether it’s the bustling street vendors of Bangkok or the enticing night markets of Taipei, Agoda offers great deals on accommodation, flights, and activities to help travelers savor every flavor.”

Agoda highlights seven street-food cities that promise travelers an unsurpassed culinary adventure:

  1. Bangkok, Thailand
    Yaowarat, one of the main streets in Bangkok’s Chinatown, is a paradise for local street-food enthusiasts. Stalls worth exploring feature Guay Jub, a peppery pork broth noodle soup, along with fresh seafood options like grilled prawns and spicy crab curry. The bustling streets offer a genuine taste of Bangkok’s culinary heritage.
  2. Ho Chi Minh City, Vietnam
    Ho Thi Ky Street is a local favorite in Ho Chi Minh City, known for its lively flower market and diverse street food offerings. Popular dishes include banh Trang Nuong (Vietnamese pizza), grilled food, and Che (sweet dessert soup). The energetic street atmosphere and friendly vendors make it an essential stop for food enthusiasts.
  3. Kuala Lumpur, Malaysia
    Jalan Alor is Kuala Lumpur’s go-to spot for street food, known for its mix of Malaysian, Thai, and Chinese flavors. From charcoal-grilled satay to stir-fried noodles, the street is lined with decades-old hawker stalls serving late into the night. Its unique mix of old-school vendors and evolving food trends makes it a key destination for both locals and tourists.
  4. Osaka, Japan
    Kuromon Ichiba Market is the epicenter of Osaka’s street food scene, where Takoyaki (octopus balls) and Okonomiyaki (savory pancakes) reign supreme. The dynamic market and lively atmosphere make it a must-visit destination for foodies.
  5. Seoul, South Korea
    South Korea topped Agoda’s Return Visitor Ranking survey as the premier food destination. In Seoul, Mangwon Market stands out as a street food paradise, offering delights like Bindaetteok (mung bean pancakes), Bibimbap, and Tteokbokki (spicy rice cakes). The market’s lively energy and traditional flavors provide an authentic taste of Korean culture.
  6. Singapore
    Lau Pa Sat is a prime location for street food in Singapore. Famous for its satay street, where skewers of grilled meat are served with peanut sauce, the historic market is a culinary hotspot. It also offers a diverse array of local dishes, including Hainanese chicken rice and Char kway teow.
  7. Taipei, Taiwan
    Ningxia Night Market is a haven for food lovers in Taipei. From oyster vermicelli to stinky tofu and braised pork rice, the market’s diverse offerings cater to every palate. The bustling stalls and crowds create an exciting culinary journey.

These cities not only offer a feast for the taste buds but also provide a cultural experience that keeps visitors coming back for more. Travelers can explore Agoda’s offerings, which include over 5 million holiday properties, more than 130,000 flight routes, and over 300,000 activities, all of which can be combined in a single booking. For more information, visit agoda.com or download the Agoda app for the best deals.

Straits Millennium Secures In-Principle Approval for MAS Major Payment Institution (MPI) License, Paving the Way for Enhanced Digital Asset Financial Solutions

SINGAPORE, Feb. 17, 2025 /PRNewswire/ — Straits Millennium Pte Ltd (“Straits Millennium”), a member of Straits Financial Group, today announced that it has obtained an in-principle approval* from the Monetary Authority of Singapore (MAS) for a Major Payment Institution (MPI) License under the Payment Services Act 2019. This significant milestone grants Straits Millennium the ability to offer digital payment token (DPT) services, reinforcing the Straits Financial Group’s position as a key player in Singapore’s rapidly evolving digital asset ecosystem.

A Strategic Move within the Digital Asset Ecosystem

As a member of the Straits Financial Group of companies—whose members provide financial services on a global scale, specializing in commodities, derivatives, and financial brokerage— Straits Millennium is uniquely positioned to bridge the gap between traditional financial markets and digital assets. This approval aligns with Singapore’s vision of becoming a global digital asset hub while ensuring strong regulatory compliance and risk management.

Straits Millennium’s new services will enable businesses and institutional investors to navigate the complexities of digital asset transactions with confidence. Straits Millennium will provide market participants with a regulated and efficient platform to facilitate the exchange of digital payment tokens and fiat currencies, ensuring competitive trade execution and adherence to industry best practices. Straits Millennium’s approach to digital asset services is anchored in compliance, security, and institutional-grade risk management.

Statement from Group CEO Jeremy Ang

Jeremy Ang, Group CEO of Straits Financial Group, expressed enthusiasm about this key milestone:

“Securing the in-principle approval for our Major Payment Institution License is a testament to our unwavering commitment to regulatory excellence, innovation, and customer-centric solutions. Singapore has established itself as a global leader in digital asset regulation, and we are proud to play a role in shaping the future of the financial industry. With our deep expertise in derivatives, commodities, and institutional financial services, we are well- positioned to provide trusted and seamless digital asset offerings to our clients. We look forward to working closely with MAS to finalize our full license and deliver best-in-class services to the market.”

Enhancing Institutional Access to Digital Assets

Amily Ho, Digital Assets Lead at Straits Millennium, emphasized the company’s focus on institutional solutions:

“The demand for compliant, seamless, and efficient digital token services continues to rise, and Straits Millennium is here to bridge that gap. Our in-principle approval allows us to build a secure and regulated ecosystem for industry players who require reliability, transparency, and scalability in their digital asset operations. Whether it’s facilitating liquidity solutions or enabling efficient trading services, we are committed to delivering innovative and regulatory- compliant services that meet the evolving needs of the market.”

The in-principle approval marks the beginning of Straits Millennium’s journey in the regulated digital asset space. The firm is actively working toward securing its full Major Payment Institution License from MAS, which will further solidify its position as a trusted and leading provider of digital asset financial services.

*An in-principle approval (IPA) reflects MAS’ view that a licence may be issued to the applicant upon the fulfilment of specified conditions and provided there are no material adverse developments affecting the applicant. An IPA does not constitute a licence for Straits Millennium Pte. Ltd. to provide payment services at this juncture. MAS reserves the right to rescind the IPA in circumstances where it considers appropriate.

About Straits Millennium

Straits Millennium is a Singapore-based digital asset financial services firm and a subsidiary of Straits Financial Group Pte Ltd. With a strong focus on regulatory compliance, institutional- grade security, and financial innovation, the company aims to bridge the gap between traditional finance and digital assets, offering seamless digital asset financial solutions tailored for today’s evolving financial landscape.

About Straits Financial Group

At Straits Financial Group, we distinguish ourselves by promoting key and innovative contracts to support the financial and commodity derivative markets as well as providing products and services to fulfill the needs of every trader.

With a strong presence in Asia and a deep understanding of the global markets, we provide value to our clients by enabling global access with a local perspective. Established in 2010, Straits Financial Group is headquartered in Singapore, and serves as the financial services arm of the CWT Group. We have established a global footprint through our presence in the United States, Indonesia, and Singapore and will continue to expand into key financial and commodity markets.

For more information, please visit our website at https://www.straitsfinancial.com.

About CWT Group

CWT Pte. Limited, headquartered in Singapore, is a multinational corporation providing integrated logistics, commodity marketing, engineering, and financial services. It is privately held by CWT International Limited (HKEX: 521) and employs around 6,000 people worldwide. For more information, please visit our website at https://www.cwtlimited.com.

 

Stryker launches ProCeed hospital bed

New hospital bed helps caregivers deliver efficient and quality care in markets outside the U.S.

PORTAGE, Mich., Feb. 17, 2025 /PRNewswire/ — Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of the ProCeed hospital bed, offering simplicity while enhancing care across various regions.

New ProCeed hospital bed helps caregivers deliver efficient and quality care in markets outside the U.S.
New ProCeed hospital bed helps caregivers deliver efficient and quality care in markets outside the U.S.

Over the last several years, nursing staff turnover has increased, and a significant percentage of frontline nurses across the globe have considered leaving their roles1. As hospitals continue to face nursing shortages and staff burnout2, patient care equipment, like beds, need to endure a heavy workload and provide staff with a straightforward experience. ProCeed was built to withstand the demands of healthcare and provide staff with a durable and cleanable hospital bed.

“As we designed ProCeed, helping keep clinicians and patients safe while allowing for an efficient and easy-to-use platform was key,” said Scott Sagehorn, vice president and general manager of Stryker’s Acute Care business. “Launching a bed that meets the needs of staff and patients in these markets will help deliver consistent and quality care.”

ProCeed helps keep patients and care teams safe with various design elements, including low bed height, which supports patient mobility and reduces the risk of injury from falls. The fifth wheel, an extra wheel positioned at the core of the bed, reduces start-up push force and offers steering help to reduce the risk of caregiver back injuries. ProCeed also offers two headboard designs, including one that stays stationary as the bed frame tilts, or a mobile headboard that tilts, raises and lowers as the frame articulates into different positions.

To learn more about ProCeed, please visit our website.

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com

1: Jester R. Editorial – Global shortage of nurses – Rebecca Jester for May 2023 issue. Int J Orthop Trauma Nurs. 2023 May;49:101018. doi: 10.1016/j.ijotn.2023.101018. Epub 2023 Mar 24. PMID: 37041090; PMCID: PMC10038672.

2: Recover to rebuild: Investing in the Nursing Workforce for Health System Effectiveness – James Buchan and Howard Catton for March 2023 issue. International Council of Nurses. 2023 March;26.

A healthcare professional must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that healthcare professionals be appropriately trained in the use of any particular product before use.

The information presented is intended to demonstrate the breadth of Stryker product offerings. A healthcare professional must always refer to the package insert, product label and/or Instructions for Use before using any Stryker product.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: ProCeed, Stryker. All other trademarks are trademarks of their respective owners or holders.

Media contact
Meghan Menz
Sr. Director, Communications
meghan.menz@stryker.com

 

WSPN Pioneers Stablecoin 2.0 at Consensus Hong Kong 2025

SINGAPORE, Feb. 17, 2025 /PRNewswire/ — WSPN (Worldwide Stablecoin Payment Network) is thrilled to announce its participation in Consensus Hong Kong 2025, marking a significant milestone in the evolution of digital finance. As stablecoins emerge as a transformative force in global finance, with ARK Invest forecasting a $1.4 trillion market by 2030, WSPN is pioneering innovative Stablecoin 2.0 solutions that are reshaping the future of digital payments.

During Consensus Hong Kong on February 19-20, 2025, WSPN will showcase its cutting-edge stablecoin solutions at Booth #2103. Visitors will experience firsthand how WSPN’s technology is driving this trillion-dollar market transformation through more efficient, secure, and transparent payment solutions while ensuring financial stability.

On the eve of the main conference, WSPN, together with industry leaders Solana, RedotPay, and MetaEra, will host an exclusive cocktail reception: “Stable Rise – Stablecoin 2.0: Future of Digital Payment”. This high-profile gathering aims to unite visionaries and innovators who are actively shaping the future of digital payments.

The reception will feature insightful keynote speeches from industry leaders, premium networking opportunities, and discussions on the future of digital payments. Attendees will gain firsthand insights into the technology driving the next trillion-dollar market while exploring partnership opportunities in the rapidly growing Asia Pacific region, solidifying WSPN’s role as a pioneer in the stablecoin ecosystem.

Event Details:

  • WSPN at Consensus Hong Kong 2025: February 19-20, 2025, Booth #2103, Hong Kong Convention and Exhibition Centre
  • “Stable Rise – Stablecoin 2.0: Future of Digital Payment” Cocktail Party: February 18, 6:30 PM – 9:30 PM, Conrad Hong Kong Garden Cafe Terrace. Register here: https://lu.ma/7ebuj5cd

Visit WSPN at Consensus Hong Kong 2025 to discover the future of digital payments through our Stablecoin 2.0 technology. Don’t miss our exclusive cocktail reception to engage with industry leaders and be part of the conversation shaping the future of stablecoins.

About WSPN

WSPN is a leading provider of next-generation stablecoin infrastructure, committed to building a more secure, efficient, and transparent payment solution for the global economy. Their flagship product, WUSD stablecoin, is pegged 1:1 to the U.S. Dollar and aims to optimize secure digital payments for Web3 users. WSPN ‘s Stablecoin 2.0 approach prioritizes user-centricity, community governance, and accessibility, paving the way for widespread stablecoin adoption.

Learn more: www.wspn.io | X | LinkedIn

CNOOC Limited Announces Buzios7 Project Commences Production

HONG KONG, Feb. 17, 2025 /PRNewswire/ — CNOOC Limited (the “Company”, SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces that Buzios7 Project has commenced production safely.

Buzios oilfield is located in the Santos Basin, southeast offshore of Brazil, with a water depth of 1,900 to 2,200 meters. It is the largest deep-water pre-salt oilfield in the world. Buzios7 is the sixth project commissioned of the oilfield. It will be developed with an FPSO and subsea production system. 15 development wells are planned to be put into production, including 7 oil producers, 6 water and gas injectors, 1 convertible well and 1 gas injector. With Buzios7 on-stream, Buzios oilfield is expected to produce up to 1 million barrels of crude oil per day in the second half of 2025.

The FPSO used in Buzios7 project is one of the largest FPSOs in the world, with a processing capacity higher than the industry average. It was converted in China in July 2024 and arrived at the oilfield in October the same year. The FPSO is able to produce up to 225,000 barrels of crude oil, process 12 million cubic meters of natural gas per day and store 1.4 million barrels of crude oil. In addition, it is equipped with closed flare to reduce greenhouse gas emissions, and heat recovery devices to reduce energy consumption.

CNOOC Petroleum Brasil Ltda , a wholly-owned subsidiary of the Company, holds a 7.34% interest in the Buzios Shared Reservoir, while the operator Petrobras holds 88.99%, and CNODC Brasil Petróleo e Gás Ltda holds 3.67%.

— End —

Notes to Editors:

More information about the Company is available at http://www.cnoocltd.com.

*** *** *** ***

This press release includes forward looking information, including statements regarding the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial results. The words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company as of this date in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company’s expectations, including but not limited to those associated with macro-political and economic factors, fluctuations in crude oil and natural gas prices, the highly competitive nature of the oil and natural gas industry, climate change and environmental policies, the Company’s price forecast, mergers, acquisitions and divestments activities, HSSE and insurance policies and changes in anti-corruption, anti-fraud, anti-money laundering and corporate governance laws and regulations.

Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements. The Company cannot assure that the results or developments anticipated will be realised or, even if substantially realised, that they will have the expected effect on the Company, its business or operations.

*** *** *** ***

For further enquiries, please contact:

Ms. Cui Liu
Media & Public Relations
CNOOC Limited
Tel: +86-10-8452-6641
Fax: +86-10-8452-1441
E-mail: mr@cnooc.com.cn 

Mr. Bunny Lee
Porda Havas International Finance Communications Group
Tel: +852 3150 6707
Fax: +852 3150 6728
E-mail: cnooc.hk@pordahavas.com 

Moby, a Leading Options Protocol, Expands to Berachain Mainnet

–    Moby’s Strategic Expansion to Scale Institutional-Grade Trading and Structured Products

–    Pioneering Options Innovation: RFA-Selected Moby Enhances Liquidity Berachain’s PoL 

SINGAPORE, Feb. 17, 2025 /PRNewswire/ —  Moby, the No.1 options protocol on Arbitrum with a total trading volume of $3.5 billion, has officially launched on the Berachain Mainnet.

Moby, a Leading Options Protocol, Expands to Berachain Mainnet
Moby, a Leading Options Protocol, Expands to Berachain Mainnet

Berachain is an EVM-identical Layer 1 blockchain that leverages the novel Proof of Liquidity (PoL) consensus mechanism, setting it apart from traditional proof-of-stake (PoS) networks. By embedding liquidity provisioning into its core security model, PoL aligns incentives across validators, applications, and users—ensuring liquidity and security at the network level.

Moby’s pioneering efforts have been recognized through its selection for Berachain’s prestigious Request for Application (RFA) program—an endorsement reflecting the protocol’s robust infrastructure and potential to enhance liquidity across the Berachain ecosystem. Moreover, Moby has secured partnerships with key industry players such as Kodiak, Infrared, PumpBTC and GMX, further solidifying its position within the ecosystem.

Moby offers two key advantages for Berachain traders and institutions: deeper liquidity and exceptionally tight spreads, both designed to ensure an optimal trading environment. Meanwhile, liquidity providers benefit from high passive income, underpinned by stable risk management achieved through real-time automatic hedging.

Additionally, Moby’s Structured Product Vault (SPV) seamlessly integrates with Berachain’s PoL mechanism, providing an efficient yield-enhancing solution. The SPV aggregates PoL rewards and optimizes their yield through algorithmic options trading. It will integrate LST/LRT and Real World Assets (RWA) to expand the on-chain options market.

“The expansion to Berachain is a pivotal step for Moby,” stated Ben, CEO of Moby. “By leveraging Berachain’s PoL model, we are setting the stage for a more liquid and scalable on-chain options market—ushering in a new era of institutional-grade trading and structured products”

Coinciding with its official launch on the Berachain mainnet, Moby introduced an incentive program for early access users. This initiative allows users to earn rewards based on their engagement.

Moby Contacts

Team Moby
team@moby.trade

About Moby

Moby is an on-chain options protocol to lead the next narrative for DeFi. Moby offers an optimized trading environment based on its pioneering SLE (Synchronized Liquidity Engine) and Dynamic Risk Premium model, which enables real-time accurate pricing, narrowest spread in the market, abundant liquidity, and Robinhood-class UI/UX.

Moby is set to provide new features such as capital efficiency improvement models and structured products to welcome institutions and the traditional TradFi audience.

 Website  Twitter  Discord  Docs  Blog  Telegram

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that its first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, has received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immune checkpoint inhibitor therapy and platinum-based chemotherapy. IBI363 has demonstrated encouraging efficacy and safety across multiple solid tumor types. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI363 mainly in China and the U.S.

At the World Conference on Lung Cancer (WCLC) in September 2024, IBI363 presented promising efficacy signals in patients with sqNSCLC who had previously received immunotherapy:

  • In the 3 mg/kg dose group, among patients with at least 12 weeks of follow-up or study completion (n=18), the objective response rate (ORR) was 50.0%, and the disease control rate (DCR) was 88.9%. The median progression-free survival (PFS) has not yet been reached and remains under follow-up.
  • In the 1/1.5 mg/kg dose group, the median PFS was 5.5 months (95% CI: 1.5, 8.3), with a 12-month PFS rate of 30.7%, highlighting the potential long-term benefits of immunotherapy.
  • Across the 1/1.5/3 mg/kg dose groups, patients with PD-L1 TPS<1% (n=22) and those with PD-L1 TPS≥1% (n=22) achieved encouraging ORRs of 36.4% and 31.8%, respectively, suggesting IBI363's potential advantage in PD-L1 low-expression populations.

Dr. Hui Zhou, Senior Vice President of Innovent, stated, “We are pleased that IBI363 has been granted Fast Track Designation by the FDA for sqNSCLC, following its previous designation for melanoma. Earlier, we reported that in an expanded cohort of sqNSCLC patients, IBI363 showed a trend toward improved ORR and DCR at higher doses, along with a manageable safety profile. The latest PFS data from the 3 mg/kg dose group after longer follow-up further strengthens our confidence in IBI363’s potential as an immunotherapy offering long-term benefits to patients. We will present the relevant data at upcoming academic conferences this year. More encouragingly, IBI363 has demonstrated potent anti-tumor activity regardless of PD-L1 expression levels. This suggests that IBI363 may not only advance treatment for immunotherapy-resistant populations but also for cold tumors with low or no PD-L1 expression. In addition to lung cancer, we have observed encouraging efficacy signals in cold tumors, including colorectal cancer and mucosal melanoma, with melanoma already advancing to pivotal clinical stages. Moving forward, we will continue to explore IBI363 in early-line treatment and in combination therapies.”

Fast Track Designation (FTD) is a regulatory process designed to expedite the clinical development and review of drugs intended to treat serious conditions and address unmet medical needs. Drug candidates granted FTD benefit from increased communication with the FDA throughout subsequent drug development, potentially accelerating their clinical development and approval process.

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein))

IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 bispecific antibody fusion protein designed to enhance efficiency while minimizing toxicity. The IL-2 arm of IBI363 has been engineered to optimize therapeutic effects with reduced side effects, while the PD-1 binding arm enables PD-1 blockade and selective IL-2 delivery. By simultaneously inhibiting the PD-1/PD-L1 pathway and activating the IL-2 pathway, IBI363 facilitates more precise and efficient targeting and activation of tumor specific T cells. Preclinical studies have shown that IBI363 exhibits strong anti-tumor activity across multiple tumor-bearing pharmacological models, including those resistant to PD-1 inhibitors and metastatic models. Additionally, it has demonstrated a favorable safety profile in preclinical models. Clinical trials are currently underway in China, the United States, and Australia to evaluate its safety, tolerability and preliminary efficacy in subjects with advanced malignancies.

About Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Lung cancer is the most common and deadliest malignancy worldwide, including in China[1], posing a significant public health challenge. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases[2], with squamous cell carcinoma being one of its two major subtypes[2]. In recent years, immune checkpoint inhibitors have transformed the treatment landscape for NSCLC. However, for patients with NSCLC who have failed immunotherapy and lack driver gene mutations, there remains a significant and urgent unmet need for effective treatment options. The standard second- or third-line treatment, docetaxel, offers limited efficacy, with a median progression-free survival (PFS) of less than four months[3],[4]. While antibody-drug conjugates (ADCs) have shown promise, two large Phase 3 studies in squamous NSCLC have yet to demonstrate satisfactory efficacy[3],[4].

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 14 products in the market. It has 3 new drug applications (NDA) under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References:

1 Globocan 2022 (version 1.1) – 08.02.2024

2 NCCN guidelines (NSCLC, version 3.2025)

3 J Clin Oncol . 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544.

4 J Clin Oncol . 2024 Aug 20;42(24):2860-2872. doi: 10.1200/JCO.24.00733.